
In 2017, many new and promising therapeutic innovations entered uro-oncology. Immunotherapy was highly topical and was intensively discussed at the annual meetings. This review summarises the news, together with future developments in the diagnosis and treatment of prostate, bladder and kidney cancer. Within the last year, there have been major developments in the treatment of hormone sensitive metastastic prostate cancer, metastatic transitional cell carcinoma and metastastic renal cell cancer. Many new drugs will be added to our therapeutic arsenal during the upcoming months.